Connect with us

Health

Tuberculosis Emerges as Leading Infectious Disease, Affecting 10.8 Million People Worldwide

Published

on

Tuberculosis Emerges as Leading Infectious Disease, Affecting 10.8 Million People Worldwide

In a resurgence that has health officials alarmed, tuberculosis (TB) has once again claimed the title of the world’s deadliest infectious disease, with new cases reaching a record high of 10.8 million in 2023, according to the World Health Organization (WHO). This represents a stark increase from the 10.1 million cases recorded in 2020, illustrating the ongoing challenge in managing this ancient but persistent disease.

TB, a highly contagious airborne infection primarily targeting the lungs, is fueled by factors like undernutrition, HIV, diabetes, smoking, and alcohol abuse. Despite a drop in TB-related deaths, the toll remains high, with 1.25 million fatalities recorded last year, placing TB above COVID-19 as the leading infectious cause of death for the first time in three years.

The global distribution of TB cases highlights significant regional and national disparities. India accounts for 26% of all new cases, followed by Indonesia at 10%, with China, the Philippines, and Pakistan each contributing over 6%. Southeast Asia, Africa, and the Western Pacific emerged as the hardest-hit regions, collectively representing 86% of cases.

“TB occurs in every part of the world,” said Dr. Tereza Kasaeva, head of WHO’s global TB program, during a recent press briefing. “But we are not on track to eliminate it.”

Challenges in Containment

Despite advances in TB treatments, rapid diagnostics, and ongoing vaccine research, Kasaeva expressed concern that global efforts are falling short of the United Nations General Assembly (UNGA) targets set for 2027. These targets aim to provide rapid diagnostic testing and preventive treatment to those at risk, yet only 48% of newly diagnosed TB patients received a rapid test last year. Among high-risk groups, 56% of individuals with HIV and 21% of household contacts of TB patients received preventive care.

Drug-resistant TB remains a significant hurdle. In 2023, an estimated 400,000 people developed multi-drug-resistant TB, though only 44% of these patients were accurately diagnosed and treated. This lack of treatment access is particularly troubling, as drug-resistant TB requires more costly and complicated care. “Drug-resistant TB continues to pose a major public health threat,” Kasaeva warned, underscoring the need for timely access to effective treatments.

Funding Shortfalls Impede Progress

The UNGA has set a funding target of $22 billion to combat TB through prevention, diagnostics, and treatment. However, as of last year, only 26% of this goal had been met, with $5.7 billion allocated worldwide. Research funding is similarly limited, with only $1 billion allocated toward the $5 billion target in 2022. Kasaeva highlighted the pressing need for increased investment, noting that low- and middle-income countries are especially constrained by the current funding gap.

Despite these financial challenges, there are promising developments in TB vaccine research. Six vaccine candidates are in late-stage clinical trials, with the WHO optimistic that a new TB vaccine could become available within the next few years. “We’re seeing clinical trials in the hardest-hit countries, and preparations for vaccine distribution should begin now,” Kasaeva noted, expressing hope for future breakthroughs.

With cases of drug-resistant TB rising and funding for prevention and care lagging, health officials are calling for urgent international support to bridge financial and logistical gaps. The resurgence of TB underscores the need for a comprehensive, well-funded approach to contain what remains a leading cause of death worldwide.

Health

Papua New Guinea Launches Emergency Polio Response After New Cases Detected

Published

on

Health authorities in Papua New Guinea have launched an urgent national vaccination campaign following the detection of two polio cases in children, marking the country’s first confirmed outbreak of the virus since 2018.

The Ministry of Health confirmed this week that poliovirus was found in two otherwise healthy children during routine screenings. Subsequent testing of sewage samples in Lae, the country’s second-largest city, verified that the virus is circulating in the community.

Health Minister Elias Kapavore described the situation as “serious but manageable” and urged swift action. “We’ve dealt with this before and know what works,” he said in a public statement, referring to a previous outbreak in 2018 that resulted in 26 cases of paralysis.

Although Papua New Guinea was declared polio-free in 2000, the recent cases underscore the country’s vulnerability due to persistently low vaccination rates among children. Polio, a highly contagious viral disease, primarily affects children under five and can lead to irreversible paralysis or death in severe cases. The disease has been largely eradicated globally, with only a few endemic regions remaining, such as Afghanistan and Pakistan.

The United Nations Children’s Fund (UNICEF) is working closely with the government to support the emergency vaccination drive. “While the focus right now is on stopping this outbreak, we must take this opportunity to boost routine immunisation to 90 per cent and protect children long-term,” said Dr Veera Mendonca, UNICEF’s representative in Papua New Guinea.

Mendonca emphasised that a long-term strategy to raise routine immunisation coverage is essential to prevent future outbreaks. UNICEF is also assisting in disease surveillance and public education efforts to raise awareness of the risks posed by polio and the importance of vaccination.

The outbreak response will target communities across the country, with particular focus on areas with the lowest immunisation coverage. Health officials are urging parents to ensure their children receive the polio vaccine, which remains the only effective way to prevent infection.

With a population of nearly 12 million and significant logistical challenges in remote areas, ensuring high vaccination coverage will be a complex task. However, authorities remain confident in their ability to contain the outbreak with coordinated action and international support.

Continue Reading

Health

Healthy Diet May Delay Onset of Menstruation, Study Finds

Published

on

A healthy diet may help delay the onset of menstruation in young girls, potentially reducing their risk of several health issues later in life, according to new research published in the journal Human Reproduction.

The study, conducted by researchers at the Fred Hutchinson Cancer Center in the U.S., followed over 7,500 girls between the ages of 9 and 14 to explore the link between dietary habits and the timing of their first menstrual periods. Girls who adhered to the healthiest diets were found to be 16% less likely to experience early menstruation compared to those with the poorest dietary habits.

In contrast, girls who consumed the most inflammatory foods — such as processed meats, sugary drinks, and refined carbohydrates — were 15% more likely to begin menstruating at an earlier age. These results were independent of body size, reinforcing the impact of diet quality regardless of a child’s weight or height.

These findings demonstrate the importance of a healthy diet regardless of body size,” said Dr. Holly Harris, lead author of the study and associate professor at Fred Hutchinson Cancer Center. “This is particularly relevant as early menstruation has been associated with long-term health risks including obesity, type 2 diabetes, cardiovascular disease, and breast cancer.”

Typically, girls begin puberty between the ages of 8 and 13, with menstruation occurring roughly two years after breast development. However, a trend toward earlier onset of puberty has raised concerns among health professionals, especially given its links to chronic illnesses in adulthood.

While the study highlights a possible role for diet in influencing menstrual timing, some experts have cautioned against drawing firm conclusions. Dr. Imogen Roger, a research fellow at Brighton and Sussex Medical School, noted that the data may reflect “reverse causation” — suggesting that the timing of puberty itself might influence dietary choices, rather than the reverse.

Diet was assessed close to the time of menarche for many of the girls,” Roger told Euronews Health. “We know that diet quality can decline during adolescence, so the association may not be entirely one-way.”

Nonetheless, researchers agree that ensuring children have access to nutritious foods — particularly during the crucial developmental window around puberty — is vital. Harris emphasized the importance of school meal programmes grounded in evidence-based nutrition.

This research reinforces the need for equitable access to healthy meals for all children and adolescents, especially through school-based initiatives,” she said.

Continue Reading

Health

Europe Pays Less for Medicines Than the U.S., but Prices Still Vary Widely by Country

Published

on

As former U.S. President Donald Trump reignites debate over America’s high drug prices, attention is once again turning to how Europe manages to pay far less for the same medicines—even if pricing remains inconsistent across the continent.

Trump, speaking to journalists on Monday, criticized the European Union for what he called “brutal” and “nasty” tactics in negotiating with pharmaceutical companies. He announced a proposal to link U.S. drug prices to the lowest rates paid by other wealthy nations, declaring: “We’re going to pay what Europe pays.”

According to a RAND Corporation analysis, the U.S. spent $617.2 billion (€542.7 billion) on pharmaceuticals in 2022—nearly three times the €205.3 billion spent by 24 European countries combined.

While it’s true that Europeans generally pay less, the picture within the region is far from uniform. A report by the World Health Organization (WHO) found that drug prices vary widely across Europe, largely due to confidential negotiations with drugmakers, national budget constraints, and differing approaches to price regulation.

In Switzerland, per capita spending on medicines reached €525, whereas Croatia spent just €262. These discrepancies reflect not only national income levels but also the complex and opaque nature of price-setting in the region. “There’s essentially no transparency,” said Huseyin Naci, an associate professor of health policy at the London School of Economics.

Many European countries base their pricing on what other nations pay and use cost-effectiveness assessments to determine value. England and Sweden emphasize whether a drug justifies its cost, while Germany looks at how much additional benefit it offers over existing treatments.

Still, costs have risen across the continent. In Germany, for instance, hospital drug prices increased 11.5% from 2012 to 2022, while retail pharmacy prices rose 2.6% in the same period. Health insurers have warned that rising prices are putting pressure on public health budgets.

If U.S. policy changes or drug companies push European nations to raise their prices, it would be highly disruptive,” Naci said.

European nations also differ in how drug costs are shared between public systems and individuals. In Cyprus, 90% of medicine expenses were covered by government or mandatory schemes in 2022. In Bulgaria, that figure was only 23%. Meanwhile, patients in some countries still pay out-of-pocket or through co-payments, depending on the condition being treated.

Despite lower overall spending, experts caution that European healthcare systems are already stretched thin. “There’s not much room left to absorb higher pharmaceutical costs,” Naci said.

Continue Reading

Trending